RT @jonotter: This isn't a journal I would usually turn to, but it's a magnificent review article with a global perspective on the economic…
RT @jonotter: This isn't a journal I would usually turn to, but it's a magnificent review article with a global perspective on the economic…
RT @jonotter: This isn't a journal I would usually turn to, but it's a magnificent review article with a global perspective on the economic…
RT @worldsis_org: Highlighting the gaps in quantifying the economic burden of surgical site infections associated with antimicrobial-resist…
RT @jonotter: This isn't a journal I would usually turn to, but it's a magnificent review article with a global perspective on the economic…
RT @worldsis_org: Highlighting the gaps in quantifying the economic burden of surgical site infections associated with antimicrobial-resist…
RT @worldsis_org: Highlighting the gaps in quantifying the economic burden of surgical site infections associated with antimicrobial-resist…
Highlighting the gaps in quantifying the economic burden of surgical site infections associated with antimicrobial-resistant bacteria | World Journal of Emergency Surgery @WSESurgery https://t.co/abianjRyLG
Someone's prepping a talk on SSI then..
RT @jonotter: This isn't a journal I would usually turn to, but it's a magnificent review article with a global perspective on the economic…
This isn't a journal I would usually turn to, but it's a magnificent review article with a global perspective on the economic burden of SSI and AMR https://t.co/yhOLB7wOzV
Surgical site infection is the leading cause of substantial burden worldwide. It is the third most costly type of healthcare-acquired infection with an estimated cost of US $20,785 per patient case. This is @BotanixPharma's BTX 1801 first application. http